Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...

With induced pluripotent stem (iPS) cells making inroads into more and more areas of biology, two groups have now used the technology to generate models of the blood-brain barrier and pinpoint new molecular mechanisms contributing...

TECHNOLOGY: Cell models iPS cell-derived brain microvascular endothelial cells could serve as BBB models for HD or Allan-Herndon-Dudley syndrome. The cells were generated by co-culturing iPS cells derived from patients in endothelial cell-conditioned media with...

TECHNOLOGY: SNPs SNPs on five genomic loci could help predict the risk of glioblastoma multiforme (GBM) and SNPs on eight genomic loci could help predict the risk of non-GBM glioma. Genome-wide association studies in 12,496...

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Monocarboxylic acid transporter 2 (SLC16A7; MCT2) Studies in mice suggest agonizing MCT2 could help treat sleep apnea-induced stroke. In a mouse model of sleep...

A team of Belgian and U.S. researchers has demonstrated that hypoxic tumor cells can be killed by targeting solute carrier family 16, member 1 (monocarboxylic acid transporter 1), a membrane lactate transporter protein expressed on...

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Solute carrier family 16, member 1 (monocarboxylic acid transporter 1) (SLC16A1; MCT1) Cell culture and mouse studies suggest that inhibiting MCT1...